Abstract
(pts) are more likely to sustain a stroke. We apply only a moderate AC protocol to manage RBP. Data analysis in this study was done with regard to thrombembolic complications in association with the AC therapy. Methods and Materials: We analyzed data of 24 RBP pts (mean age 54.8 years, range 27 -73, 3 female, 21 male). 6 pts were supported with the HM II, 10 with the DuraHeart and 8 with VentrAssist. Underlying causes for endstage cardiac failure requiring MCS were e.g.: ICM (n 10), DCM (n 5), AMI (n 4), PPCM (n 1), Cardiogenic shock (n 1), HOCM (n 1), 7 pts had previous cardiac surgery, 1 Aortic valve replacement. All pts received mild AC therapy with coumadin, target INR level is 2-2-5, in addition to aspirin 100 mg daily. Results: Mean duration of support was 153.92 days /125.22 SD. There were 3 deaths (12.5%). One patient was successfully transplanted (4.2%) and 20 pts (83.3%) are still on support. No device thrombosis occurred. Moreover, we found no major thrombembolic complications in the 24 pts included in this analysis, especially no hemorrhagic stroke or ischemic stroke was found. One patient sustained a mild TIA, which resolved totally. Conclusions: This study proves the safety of running RBP with moderate AC and the results justify the application of these systems particularly in an older patient cohort.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call